IPSC — Century Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1850119 ·
Last close
$2.17
Market Cap
$391.37M
52W High
$3.04
52W Low
$1.93
ADV30
832,053
Next earnings
2026-08-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -23,684,000 | -21,645,000 | 326,553,000 | 51,048,000 | 61,809,000 |
| Dec 2025 | 0 | — | -20,651,000 | -19,171,000 | 223,704,000 | 61,853,000 | 64,768,000 |
| Sep 2025 | 0 | — | -29,361,000 | -34,422,000 | 244,717,000 | 55,515,000 | 68,369,000 |
| Jun 2025 | 0 | — | -34,664,000 | -32,541,000 | 284,692,000 | 56,878,000 | 74,794,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-103,876,000
Investing CF
$107,501,000
Financing CF
$173,000
CapEx
$-987,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.26
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-791,917,000
Inventory
—
Receivables
$667,000
ST Investments
$55,261,000
EBIT TTM
$-10,500,000
Pretax Income TTM
$-9,642,000
Interest Exp TTM
$0
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$0
EBITDA
$-101,596,000
Free Cash Flow
$-53,628,000
Enterprise Value
$304,591,936
Total Cash
$134,803,008
Total Debt
$48,025,000
Shares Out
180,354,809
Trailing EPS
$-1.13
Book Value
$1.82
ROE
-42.7%
ROA
-22.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 109,164,000 | -10,506,000 | -9,580,000 | 223,704,000 | 64,768,000 | — | -103,876,000 |
| Dec 2024 | 6,589,000 | -133,810,000 | -126,566,000 | 353,216,000 | 191,854,000 | — | -110,135,000 |
| Dec 2023 | 2,235,000 | -125,181,000 | -136,673,000 | 360,691,000 | 175,941,000 | — | -88,348,000 |
| Dec 2022 | 5,199,000 | -123,831,000 | -130,932,000 | 486,544,000 | 183,806,000 | — | 14,052,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.52
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CMPX | Compass Therapeutics, Inc. | $396.19M | $2.20 | — |
| CCCC | C4 Therapeutics, Inc. | $385.88M | $3.49 | — |
| ZURA | Zura Bio Ltd | $399.45M | $4.21 | — |
| REPL | Replimune Group, Inc. | $379.83M | $4.60 | — |
| LXEO | Lexeo Therapeutics, Inc. | $403.60M | $5.14 | — |
News headlines (Yahoo Finance, 1h cache)
Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors
2026-05-14 12:00 · Yahoo
Century Therapeutics Reports First Quarter Financial Results and Business Updates
2026-05-13 12:00 · Yahoo
H.C. Wainwright Remains Bullish on Century Therapeutics (IPSC)
2026-05-01 08:18 · Yahoo
Century Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions
2026-04-30 20:05 · Yahoo
Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates
2026-03-12 12:00 · Yahoo
Century Therapeutics to Participate in Upcoming Investor Conferences in March
2026-02-25 13:00 · Yahoo
Piper Sandler Highlights Century Therapeutics (IPSC) Cash Runway Through 2029, Upcoming IND Submission
2026-01-30 19:58 · Yahoo
Century Therapeutics (IPSC) Upgraded to Strong Buy: Here's What You Should Know
2026-01-22 17:00 · Yahoo
Promising Penny Stocks To Watch In January 2026
2026-01-16 12:05 · Yahoo
Century Therapeutics Secures Oversubscribed $135 Million Private Placement Financing to Support Lead Program, CNTY-813, a Potentially Curative Therapy for Type 1 Diabetes
2026-01-08 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.